TCR+CD3 co-transduction of T cells reduces tumor burden. (A) CD8+ T cells from Thy1.1+ C57BL/6 mice were transduced with F5-TCR, F5-TCR+CD3-GFP, or left un-transduced (Mock). Thy1.2+ C57BL/6 mice were sublethally irradiated (5.5Gy) and injected subcutaneously with 1 × 106 EL4.NP tumor cells on day 0 followed by intravenous transfer of a total of 3 × 105 transduced Thy1.1+ CD8+ T cells. Tumor volume was measured at the indicated time points. Data are from 3 experiments each with 3 mice/group. (B-C) CD8+ T cells from Thy1.1+ C57BL/6 mice were transduced with F5-TCR, F5-TCR+CD3-GFP, or left untransduced (Mock). Thy1.2+ C57BL/6 mice were sublethally irradiated (5.5Gy) and injected subcutaneously with 1 × 106 firefly luciferase-expressing EL4.NP tumor cells on day 0 followed by intravenous transfer of a total of 3 × 105 transduced CD8+ T cells the next day. Tumor growth was monitored by IVIS-100 bioluminescence camera. (B) Graph shows the mean bioluminescent signals in photons recorded at the site of tumor growth. (C) The bioluminescent signals at the site of tumor growth is shown over a 50 day period in representative mice treated with T cells expressing TCR-only or TCR+CD3-GFP. Data in panels B and C are from 2 independent experiments each with 3 mice/group.
